Will the use of an induction agent and a paralytic, such as propofol (induction agent) and rocuronium (neuromuscular blocking agent), relax the muscles controlling the epiglottis during a surgical procedure?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 5, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Neuromuscular Blocking Agents and Epiglottic Muscle Relaxation

Yes, the administration of an induction agent (such as propofol) followed by a paralytic agent (such as rocuronium) will relax the muscles controlling the epiglottis during anesthesia. This is a fundamental pharmacologic effect of neuromuscular blocking agents, which produce paralysis of all skeletal muscles, including those of the larynx and pharynx 1.

Mechanism of Muscle Relaxation

Neuromuscular blocking agents produce complete skeletal muscle paralysis by blocking acetylcholine receptors at the neuromuscular junction, affecting all voluntary muscles including those controlling the epiglottis, vocal cords, and other laryngeal structures 1. The laryngeal muscles are particularly sensitive to these agents, requiring lower concentrations for relaxation compared to peripheral muscles 1.

Specific Anatomical Effects

  • The epiglottis is controlled by laryngeal muscles that are among the most sensitive to neuromuscular blockade, meaning they relax at lower drug concentrations than other muscle groups 1
  • Both depolarizing agents (succinylcholine) and non-depolarizing agents (rocuronium, atracurium) produce complete relaxation of pharyngeal, laryngeal, and esophageal musculature 1, 2
  • The corrugator supercilii muscle is recommended as the monitoring site during anesthesia specifically because its sensitivity and kinetics closely parallel those of the laryngeal muscles, confirming that laryngeal muscle relaxation occurs with standard dosing 1, 2

Clinical Implications for Airway Management

The relaxation of epiglottic and laryngeal muscles is the intended therapeutic effect that facilitates tracheal intubation and reduces pharyngeal/laryngeal injury 1. This complete muscle relaxation:

  • Reduces pharyngeal and laryngeal injury during intubation from 22.6% to 9.7% when muscle relaxants are used (GRADE 1+ recommendation) 1
  • Facilitates optimal intubating conditions by eliminating muscle tone and reflexes that would otherwise resist laryngoscopy 1, 3
  • Creates vulnerability to upper airway obstruction immediately after induction, particularly with propofol alone, due to genioglossus suppression 4

Important Safety Considerations

The period immediately following loss of consciousness represents the highest risk for airway obstruction because propofol-induced muscle relaxation is incomplete without a neuromuscular blocker, while the genioglossus (tongue muscle) is suppressed 4. This creates a critical window where:

  • Airway patency depends on proper positioning and potential airway adjuncts until the paralytic takes full effect 4
  • Complete laryngospasm during this period may require neuromuscular blocking agents for resolution, as propofol alone is only 77% effective 4
  • Immediate availability of succinylcholine and atropine in pediatric settings reduces cardiac arrest and severe airway obstruction by nearly 50% 2

Pharmacologic Specifics

Rocuronium at standard intubating doses (0.6-1.2 mg/kg) produces complete neuromuscular blockade within 60 seconds, including full relaxation of laryngeal and epiglottic muscles 1, 5, 6. The FDA labeling confirms that rocuronium's mechanism involves blocking acetylcholine at the motor endplate, affecting all skeletal muscles 5.

  • Lower doses of rocuronium (0.1-0.2 mg/kg) are sufficient to achieve glottic opening and relax laryngeal muscles when adequate anesthetic depth is present 1, 7
  • Volatile anesthetics (isoflurane, enflurane) potentiate rocuronium's effects by 20-40%, potentially requiring dose adjustments 5
  • The duration and intensity of muscle relaxation can be monitored using train-of-four stimulation, with complete blockade indicated by absence of response 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Muscle Relaxants in Anesthesia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Rapid-sequence intubation and the role of the emergency department pharmacist.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2011

Guideline

Airway Management During Propofol Induction

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Atracurium for Muscle Relaxation in General Anesthesia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

Is 2 mg of midazolam (midazolam) the appropriate dose for rapid sequence intubation (RSI)?
What is the recommended induction dose of rocuronium (a non-depolarizing neuromuscular blocking agent) for a typical adult patient with no significant medical history?
What is the recommended dose of rocuronium (neuromuscular blocking agent) for intubation?
What is the dose of rocuronium (a neuromuscular blocking agent) for endotracheal intubation?
What is the recommended dosage of ketamine and rocuronium for Rapid Sequence Intubation (RSI)?
Is hydroxide (hydroxide ion) a suitable treatment for a patient with anxiety?
What could be the reasons for a significant increase in International Normalized Ratio (INR) from 2.6 to 5.6 in one week in a patient with a history of atrial fibrillation, deep vein thrombosis, or pulmonary embolism, and currently on warfarin (anticoagulation therapy)?
What is the most likely cause and recommended treatment for a 33-year-old man with central hypogonadism, complete loss of sexual function, anhedonia, and cognitive decline, who has a history of heavy metal exposure, gut dysbiosis, and fluctuating prolactin levels, and has normal penile Doppler and testes?
What is the best approach to medication management for an asymptomatic patient with bigeminy, considering potential underlying heart disease?
What is the initial management for a patient with atrial fibrillation (AF) and rapid ventricular response (tachycardia)?
What is the best course of action for a patient with worsening hypertrophy due to Hypertrophic Cardiomyopathy (HCM)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.